LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein

• Main Authors: Marker Daniel F, Puccini Jenna M, Mockus Taryn E, Barbieri Justin, Lu Shao-Ming, Gelbard Harris A
• Format: Article
• Language: English
• Published: BMC 2012-11-01
• Series: Journal of Neuroinflammation
• Subjects: Phagocytosis; Microglia; HIV-1; Tat; Leucine-rich repeat kinase 2 (LRRK2); AnnexinV; Parkinson’s disease; Brain-specific angiogenesis inhibitor 1 (BAI1)
• Online Access: http://www.jneuroinflammation.com/content/9/1/261

<p>Abstract</p> <p>Background</p> <p>Human Immunodeficiency Virus-1 (HIV-1) associated neurocognitive disorders (HANDs) are accompanied by significant morbidity, which persists despite the use of combined antiretroviral therapy (cART). While activated microglia play a role in pathogenesis, changes in their immune effector functions, including phagocytosis and proinflammatory signaling pathways, are not well understood. We have identified leucine-rich repeat kinase 2 (LRRK2) as a novel regulator of microglial phagocytosis and activation in an <it>in vitro</it> model of HANDs, and hypothesize that LRRK2 kinase inhibition will attenuate microglial activation during HANDs.</p> <p>Methods</p> <p>We treated BV-2 immortalized mouse microglia cells with the HIV-1 <it>trans</it> activator of transcription (Tat) protein in the absence or presence of LRRK2 kinase inhibitor (LRRK2i). We used Western blot, qRT-PCR, immunocytochemistry and latex bead engulfment assays to analyze LRRK2 protein levels, proinflammatory cytokine and phagocytosis receptor expression, LRRK2 cellular distribution and phagocytosis, respectively. Finally, we utilized <it>ex vivo</it> microfluidic chambers containing primary hippocampal neurons and BV-2 microglia cells to investigate microglial phagocytosis of neuronal axons.</p> <p>Results</p> <p>We found that Tat-treatment of BV-2 cells induced kinase activity associated phosphorylation of serine 935 on LRRK2 and caused the formation of cytoplasmic LRRK2 inclusions. LRRK2i decreased Tat-induced phosphorylation of serine 935 on LRRK2 and inhibited the formation of Tat-induced cytoplasmic LRRK2 inclusions. LRRK2i also decreased Tat-induced process extension in BV-2 cells. Furthermore, LRRK2i attenuated Tat-induced cytokine expression and latex bead engulfment. We examined relevant cellular targets in microfluidic chambers and found that Tat-treated BV-2 microglia cells cleared axonal arbor and engulfed neuronal elements, whereas saline treated controls did not. LRRK2i was found to protect axons in the presence of Tat-activated microglia, as well as AnnexinV, a phosphatidylserine-binding protein. In addition, LRRK2i decreased brain-specific angiogenesis inhibitor 1 (BAI1) receptor expression on BV-2 cells after Tat-treatment, a key receptor in phosphatidylserine-mediated phagocytosis.</p> <p>Conclusion</p> <p>Taken together, these results implicate LRRK2 as a key player in microglial inflammation and, in particular, in the phagocytosis of neuronal elements. These studies show that LRRK2 kinase inhibition may prove an effective therapeutic strategy for HANDs, as well as other neuroinflammatory conditions.</p>